![](https://cdn.benzinga.com/files/images/story/2024/07/30/national-cancer-institute-uxnbyoejxce-unsplash.jpg?width=1200&height=800&fit=crop)
Recursion to Report Q2 Earnings: What's in the Cards?
We believe that Recursion RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is likely to beat expectations when it reports second-quarter 2024 results. The Zacks Consensus Estimate is pegged at a loss of 35 cents …